AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0045
Drug name and formulations:		Riluzole oral suspension 5mg/ml (Teglutik®)
Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	No established evidence of increased patient safety with liquid formulation; risk of aspiration may still be present.
Clinical effectiveness	*Established licensed product*	Similar to tablet form. There is no evidence that Teglutik® exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. It has not been shown to be effective in the late stages of ALS.
Strength of evidence		Modest
Cost effectiveness or resource impact	*£*	Considerable resource impact (£144,000 a year based on 60 patients initiated on oral suspension). £200 per patient per month compared to £15 a month for oral tablet.
Place of therapy relative to available treatments	*1/2nd tier*	Only licensed drug for this condition. Second line to tablet form.
National guidance and priorities	*NICE, MTRAC*	NICE TA20 (2001), based on tablet formulation. NICE NG 42 (Feb 2016): MND
Local health priorities	*CCG views*	Would not support in view of resource impact
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	Would require ESCA if approved

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	**Not approved**. Rationale: very expensive medicine; the

	committee was not convinced by the argument put forward for the patient group identified for this formulation (i.e. NG/PEG feeding tubes), as the NEWT guidelines support crushing of tablets.
Formulary status (RAG) and rationale	
Implementation requirements:	
Implementation monitoring:	